A single center, prospective and randomized controlled study of the efficacy and safety of MGN-3/BioBran for patients with B-cell non-Hodgkin's lymphoma after CR

A single center, prospective and randomized controlled study of the efficacy and safety of MGN-3/BioBran for patients with B-cell non-Hodgkin's lymphoma after CR - A study of the efficacy and safety of MGN-3/BioBran for patients with B-cell non-Hodgkin's lymphoma after CR

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034569

Enrollment

Registered

2018-10-22

Start date

2015-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B-cell non-Hodgkin&#39

Interventions

patients receive 1 g of MGN-3/BioBran 3 times a day after taking a meal for 12 weeks patients receive 1 g of placebo 3 times a day after taking a meal for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -patients with B-cell non-Hodgkin's lymphoma -CR confirmed by his/her attending doctor -within 1 year after achievement of a CR -life expectancy of 1 year or more

Exclusion criteria

Exclusion criteria: -have immune suppressive agent, infectious diseases, or auto immune diseases -are allergic to rice bran

Design outcomes

Primary

Measure	Time frame
Changes in the number of white blood cells, lymphocytes, T cells, B cells and Treg cells, and adverse event, after administration of MGN-3/BioBran for 12 weeks,	—

Countries

Japan

Contacts

Public ContactSohsuke Meshitsuka

Japanese Red Cross Medical Center Division of Hematology

sohmeshi@ims.u-tokyo.ac.jp03-3400-1311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

A single center, prospective and randomized controlled study of the efficacy and safety of MGN-3/BioBran for patients with B-cell non-Hodgkin&#39;s lymphoma after CR